Instrument NameGsk Plc ADRInstrument Symbol(GSK-N)

Instrument ExchangeNYSE

While technology stocks continue to struggle, stocks in the lucrative over-the-counter healthcare products sector are thriving. One prominent such name is Haleon. Its stock has jumped more than 22% over the past three months, as sales and profits in its nine large-scale multinational, high-margin 'power brands' continue to hold leading market shares in growing categories.

Annovis Bio (NYSE: ANVS), a late-stage, clinical-drug platform company pioneering transformative therapies for neurodegenerative disorders such as Alzheimer’s disease (“AD”) and Parkinson’s disease (“PD”), has released preclinical data from a...

GSK, a multinational pharma company, scans as a bargain.

A modest amount of money can go a long way when it's put to work in highly innovative, game-changing businesses.

USA News Group News Commentary – According to the American Cancer Society, 2024 will be the first year the USA expects to have more than 2 million new cancer cases. In order to respond to the rising rates of cancer, the National Cancer...

The Food and Drug Administration recently approved a new vaccine from Moderna, but the stock dipped in response.

Earnings season is slowing down, but we still have a few big names reporting. This week, we have Alibaba, Home Depot, Walmart, Cisco and Deere & Company all reporting.

‘ESG is becoming a bit toxic. Nobody really knows what it is and what it includes or doesn’t include,’ says François Bourdon, managing partner of Nordis Capital

The Federal Trade Commission is challenging patents on 20 brand-name drugs, including the blockbuster weight-loss injection Ozempic

Wall Street analysts who watch the cancer drug developer closely think it could rocket higher.

These stocks could rocket higher, but they also present significant risks.

Several well-regarded funds run by famous billionaire investors bought shares of 23andMe during the last three months of 2023.

/CNW/ - Find Therapeutics Inc., a biopharmaceutical company focused on the development of innovative therapies for autoimmune diseases, today announced that...

The renowned brokerage firm weighed in on its top stock picks from the European market, which could offer investors better value than the outsized GRANOLAS group of equities at current levels.

GSK's stock has been a poor performer for years. But recently, the pharma stock keeps setting new 52-week highs, thanks to its blockbuster vaccines.

A survey of North American equities heading in both directions

Growth stocks are getting ready for a comeback year in 2024, and these two under-the-radar stocks have solid financials and significant upside potential.

Unlike many of its peers, GSK just reported a big year-over-year jump in vaccine sales - and there's more growth to come, as the pharmaceutical company expands both its pipeline and the geographical reach for its vaccines.

The world is a big place, and many great companies are based outside our U.S. borders.

Pharma stock GSK is a remedy for the winter blahs with a low beta, a high yield, and value for investors. Sales of new drug Arexvy underpin results.

Moderna stock soared early in the pandemic.

Viatris, GSK, and Organon are all trading at less than 7 times earnings.

GSK offers a robust dividend yield, but that's not the only thing to consider.